No significant difference was observed in rCBV between patient cohorts nor was rCBV found to be an effective differentiator of EGFR status. Univariate cox regression analysis determined both R 2' and rOEF significantly influence OS. Patients with EGFR-amplified gliomas had a significantly shorter OS than non-amplified patients. ROC analysis suggested that R 2' (AUC = 0.7190 P = 0.0048) and rOEF (AUC = 0.6959 P = 0.0156) could separate EGFR status. Kaplan-Meier survival curves were plotted and compared using the log-rank test.ĮGFR amplified gliomas exhibited significantly higher median R 2' and rOEF than non-amplified gliomas. Overall survival (OS) was determined using univariate and multivariate cox models. ROC analysis was performed to assess the ability of imaging characteristics to discriminate EGFR amplification status. Using Student t test or Wilcoxon rank-sum test, median R 2', rCBV, and rOEF were compared between EGFR-amplified and non-amplified gliomas. Reversible transverse relaxation rate (R 2'), relative cerebral blood volume (rCBV), and relative oxygen extraction fraction (rOEF) were calculated for the contrast-enhancing and non-enhancing tumor regions. This study included 72 histologically confirmed EGFR-amplified and non-amplified glioma patients. Using hypoxia-sensitive spin-and-gradient echo echo-planar imaging and perfusion MRI, we investigated the influence of EGFR amplification on tissue oxygen availability and utilization in human gliomas. growth factor receptor (EGFR) amplification promotes gliomagenesis and is linked to lack of oxygen within the tumor microenvironment. 10 Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA. 9 UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.8 Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.7 Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.6 UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.5 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.4 Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.3 Department of Bioengineering, Henry Samueli School of Engineering, University of California Los Angeles, Los Angeles, CA, USA.2 Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.1 UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |